Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes

Bibliography

• Number of people with diabetes increases to 24 million. Atlanta, GA: Centers for Disease Control and Prevention. 2008. Available from: http://www.cdc.gov/media/pressrel/2008/r080624.htm [Last accessed 27 March 2010]
   Google Scholar
• American Association of Clinical Endocrinologists/American College of Endocrinology Glycemic Control Algorithm Consensus Panel. Glycemic control algorithm. Endocr Pract 2009;10(6):541-559
   Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• McIntosh C, Demuth H, Pospisilik J, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept 2005;128:159-65
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93(12):4810-7
   PubMed Web of Science ®Google Scholar
• Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inibitors. Pharmacol Ther 2009;124:113-38
   PubMed Web of Science ®Google Scholar
• Defronzo R, Ratner R, Jan J, Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28(5):1092-100
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Hans J, Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27(11):2628-35
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock JC, Effects of Exenatide (Exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28(5):1083-91
   PubMed Web of Science ®Google Scholar
• Zinman R, Hoogwerf BJ, Garcia SD, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Vilsboll T. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lower and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care 2007;30:1608-10
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse J, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Garber A. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52-week phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, Liraglutide, a once-daily human GLP-1 analog, added to sulfonylurea (SU) offers significantly better glycemic control and favorable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes [abstract 13-OR]. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association; 6 – 10 June 2008; San Francisco, California
   Google Scholar
• Nauck MA, Frid A, Hermansen K, Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus(LEAD 2 study). Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Russel-Jones D, Vaag A, Schmitz O, Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in type 2 diabetes (LEAD 5) [abstract 536-P]. Program and abstracts of the 68th Scientific Sessions of the American Diabetes Association; 6 – 10 June 2008; San Francisco, California
   Google Scholar
• Victoza (liraglutide). EPAR summary for the public. London, UK: European Medicines Agency, 2009. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/victoza/H-1026-en1.pdf [Last accessed 27 March 2010]
   Google Scholar
• Liraglutide (marketed as Victoza). Postmarket Drug Safety Information for Patients and Providers. Rockville, MD: US Food and Drug Administration, 2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm198437.htm [Last accessed 27 March 2010]
   Google Scholar
• Information for Healthcare Professionals: Exenatide (marketed as Byetta)–8/2008 Update. Postmarket Drug Safety Information for Patients and Providers. Rockville, MD: US Food and Drug Administration, 2008. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/ucm124713.htm [Last accessed 27 March 2010]
   Google Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide – the FDAs review of a new antidiabetic therapy. NEJM 2010;362(9):774-7
   PubMed Web of Science ®Google Scholar
• Lovshin J, Drucker D. A review of incretin-based therapies for type 2 diabetes treatment. Rev Endocrinol 2009:23-27
   Web of Science ®Google Scholar
• Rosenstock J, Reusch J, Bush M, Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes. A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32(10):1880-6
   PubMed Web of Science ®Google Scholar
• Baggio L, Huang Q, Brown T, Drucker D. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-500
   PubMed Web of Science ®Google Scholar
• Bush M, Matthews J, DeBoever E, Safety, tolerability, pharmacodynamics, and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in health subjects. Diabetes Obesity Metab 2009;11:498-505
   PubMed Web of Science ®Google Scholar
• Seino Y, Nakajima H, Miyahara H, Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25(12):3049-57
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study of albiglutide in type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00849017?term=albiglutide&rank=2 [Last accessed 27 March 2010]
   Google Scholar
• A study of the pharmacokinetics of albiglutide in normal and renally impaired subjects. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00938158?term=albiglutide&rank=1 [Last accessed 27 March 2010]
   Google Scholar
• A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00838916?term=albiglutide&rank=7 [Last accessed 27 March 2010]
   Google Scholar
• A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00839527?term=albiglutide&rank=3 [Last accessed 27 March 2010]
   Google Scholar
• Efficacy and safety of albiglutide in treatment of type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00838903?term=albiglutide&rank=5 [Last accessed 27 March 2010]
   Google Scholar
• Safety and efficacy of albiglutide in type 2 diabetes. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00849056?term=albiglutide&rank=6 [Last accessed 27 March 2010]
   Google Scholar
• A study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine. Bethesda, MD: US National Institutes of Health. ClinicalTrials.gov. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00976391?term=albiglutide&rank=4 [Last accessed 27 March 2010]
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2006;29(8):1963-71
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of Diabetes. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
   PubMed Web of Science ®Google Scholar